PMID- 15104671
OWN - NLM
STAT- MEDLINE
DCOM- 20051013
LR  - 20221207
IS  - 0001-2815 (Print)
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 63
IP  - 5
DP  - 2004 May
TI  - SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical 
      validation.
PG  - 395-400
AB  - An effective Severe Acute Respiratory Syndrome (SARS) vaccine is likely to 
      include components that can induce specific cytotoxic T-lymphocyte (CTL) 
      responses. The specificities of such responses are governed by human leukocyte 
      antigen (HLA)-restricted presentation of SARS-derived peptide epitopes. Exact 
      knowledge of how the immune system handles protein antigens would allow for the 
      identification of such linear sequences directly from genomic/proteomic sequence 
      information (Lauemoller et al., Rev Immunogenet 2001: 2: 477-91). The latter was 
      recently established when a causative coronavirus (SARS-CoV) was isolated and 
      full-length sequenced (Marra et al., Science 2003: 300: 1399-404). Here, we have 
      combined advanced bioinformatics and high-throughput immunology to perform an HLA 
      supertype-, genome-wide scan for SARS-specific CTL epitopes. The scan includes 
      all nine human HLA supertypes in total covering >99% of all individuals of all 
      major human populations (Sette & Sidney, Immunogenetics 1999: 50: 201-12). For 
      each HLA supertype, we have selected the 15 top candidates for test in 
      biochemical binding assays. At this time (approximately 6 months after the genome 
      was established), we have tested the majority of the HLA supertypes and 
      identified almost 100 potential vaccine candidates. These should be further 
      validated in SARS survivors and used for vaccine formulation. We suggest that 
      immunobioinformatics may become a fast and valuable tool in rational vaccine 
      design.
FAU - Sylvester-Hvid, C
AU  - Sylvester-Hvid C
AD  - Division of Experimental Immunology, Institute of Medical Microbiology and 
      Immunology (IMMI), University of Copenhagen, Building 18.3, Panum Institute, 
      Blegdamsvej 3, 2200 Copenhagen N, Denmark.
FAU - Nielsen, M
AU  - Nielsen M
FAU - Lamberth, K
AU  - Lamberth K
FAU - Roder, G
AU  - Roder G
FAU - Justesen, S
AU  - Justesen S
FAU - Lundegaard, C
AU  - Lundegaard C
FAU - Worning, P
AU  - Worning P
FAU - Thomadsen, H
AU  - Thomadsen H
FAU - Lund, O
AU  - Lund O
FAU - Brunak, S
AU  - Brunak S
FAU - Buus, S
AU  - Buus S
LA  - eng
GR  - AI 49213-02/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A3 Antigen)
RN  - 0 (Peptides)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Antigen Presentation
MH  - Computational Biology
MH  - Epitopes, T-Lymphocyte/immunology
MH  - Genome, Viral
MH  - HLA Antigens/*immunology
MH  - HLA-A Antigens/immunology
MH  - HLA-A3 Antigen/immunology
MH  - Humans
MH  - Neural Networks, Computer
MH  - Peptides/immunology
MH  - Protein Binding
MH  - Severe acute respiratory syndrome-related 
      coronavirus/genetics/*immunology/isolation & purification
MH  - Severe Acute Respiratory Syndrome/immunology/*therapy
MH  - Viral Vaccines/*immunology
PMC - PMC7161580
EDAT- 2004/04/24 05:00
MHDA- 2005/10/14 09:00
PMCR- 2020/04/16
CRDT- 2004/04/24 05:00
PHST- 2004/04/24 05:00 [pubmed]
PHST- 2005/10/14 09:00 [medline]
PHST- 2004/04/24 05:00 [entrez]
PHST- 2020/04/16 00:00 [pmc-release]
AID - TAN221 [pii]
AID - 10.1111/j.0001-2815.2004.00221.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2004 May;63(5):395-400. doi: 10.1111/j.0001-2815.2004.00221.x.